- Company
- Schingles is expected to be released in the end of the year
- by Apr 21, 2021 05:50am
- GSK's Schingles, which boasts the highest efficacy among the existing shingles vaccines, is expected to receive product approval at the end of the year as soon as possible. When Schingles is released in Korea, fierce competition is expected with Zostavax and Sky Zoster. According to the pharmaceutical industry on the 21st, GSK applied for
- Policy
- AZ vaccine’s import authorization still under review
- by Lee, Tak-Sun Apr 21, 2021 05:50am
- Attention has been rising on the reason for the delayed approval of the imported AstraZeneca’s COVID-19 vaccine, which was the first vaccine to submit its application in Korea. Although the Ministry of Food and Drug Safety (MFDS) had shortened the review period to 40 days, 3 months have passed and no news on the approval of the importe
- Company
- Lynparza tablet to be prescribed at Big 5 hospitals
- by Eo, Yun-Ho Apr 21, 2021 05:49am
- The tablet formulation of the anticancer drug ‘Lynparza’ can now be prescribed at the Big-5 tertiary hospitals. Industry sources reported that AstraZeneca’s poly ADP ribose polymerase (PARP) inhibitor Lynparza (olaparib) passed the review of drug committees (DC) in the five major hospitals, the ‘Big-5s,’ which include the Samsung
- Policy
- The domestic COVID-19 vaccine is still some way off
- by Lee, Jeong-Hwan Apr 21, 2021 05:49am
- It was pointed out that amid intensifying competition in countries around the world over the supply and demand of COVID-19 vaccine, there is a low possibility that a domestic vaccine will be marketed within this year, increasing public anxiety. Compared to the fact that about three domestic-made COVID-19 treatments are expected to be marketed
- Product
- Korean bio-pharma companies attract attention at AACR 2021
- by Whang, byung-woo Apr 21, 2021 05:49am
- The AACR 2021 Annual Meeting, the largest meeting on cancer research in the world, took place from April 10th to April 15th. At the meeting, new combination therapies were introduced, raising expectations for the use of new mechanisms of action in the field of cancer treatment. Through a presentation of data on the use of nivolumab (Opdivo) i
- Company
- Generics for Eliquis are sold out
- by Apr 20, 2021 09:13am
- The production and sales of generics that lost Eliquis(Apixaban)' patent dispute were halted. According to the drug distribution industry on the 16th, generic for Eliquis companies stopped producing and selling items at once after the Supreme Court ruling. There is some inventory that has been passed to wholesalers. Generics for Eliquis
- Company
- SG&A ratio fell in 3 out of 4 MNCs...a COVID-19 Impact?
- by An, Kyung-Jin Apr 20, 2021 06:03am
- Korean subsidiaries of multinational pharmaceutical companies have lowered their selling, general & administrative (SG&A) to sales ratio last year due to the prolonged COVID-19 crisis. Analysts predict that the cost-cutting measure was made in response to the disruptions in face-to-face sales and marketing activities caused by the pandemic.
- Company
- Rx drug market recovers after flu season
- by Chon, Seung-Hyun Apr 20, 2021 06:02am
- The outpatient prescription drug market, which was slow in winter, is showing a recovery trend. Since the end of last year, the total prescription drug volume has been on a decline compared to the previous year, but in March it turned to an upward trend. It is analyzed that COVID-19 showed sluggishness due to a sharp decline in infectious diseas
- Company
- Domestic Sputnik V CMO meets with MOHW for discussions
- by Kim, Jin-Gu Apr 20, 2021 06:02am
- With the possibility of using ‘Sputnik V' rising in Korea, various industry sources have confirmed that a Korean CMO of this Russian vaccine has had a meeting with Korea's Ministry of Health and Welfare (MOHW). According to industry officials, one of the companies that signed a CMO deal for Sputnik V has recently had a meeting with a
- Company
- Hemophilia B tx, Benefix, took the lead with weekly therapy
- by Apr 20, 2021 06:02am
- Pfizer Korea's Benefix (nonacog alfa)', which has been used for the treatment of hemophilia B patients in Korea for 15 years, has taken the lead as a once-a-week prophylaxis. The strategy for treating hemophilia has now become routine prophylactic therapy. The World Federation of Hemophilia recommended prophylaxis as standard treatment in
